StreetAlpha.app
Home › Stocks › PALI

Palisade Bio, Inc. (PALI)

Healthcare
$0.84
▼ −9.24%
LAST CLOSE · NOV 20

Palisade Bio develops oral drug candidates for inflammatory bowel disease, led by PALI-2108 for ulcerative colitis and Crohn's disease. It last closed at $0.84 on Nov 20, down 9.24% on the day. The next earnings report for PALI is expected around Tue, Feb 9, 2027, after the close. For the quarter ended Sep 2026, PALI reported EPS of -$0.07 on revenue of $0. Over its last 5 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months PALI insiders bought $347K of stock on the open market and sold $420K, according to SEC Form 4 filings.

AI Auto Pilots
Is PALI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PALI.

Key Stats

Last 12 months
Results
Revenue
$500K
Net income
−$43.7M
−8739.2% margin
Operating margin
−9625.4%
−$48.1M operating income
Valuation
Market cap
$150.6M
179.3M shares
P/E
–
Price to sales
301.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$113.6M
At Sep 30
Shareholder equity
$112.4M
Shares outstanding
179.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $250K$250KFY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From PALI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 9
Estimated date · After the close
Reported EPS
-$0.07
Quarter ended Sep 2026
Year ago EPS
-$0.38
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.69Dec '24Mar 2025: -$0.47Mar '25Jun 2025: -$0.58Jun '25Sep 2025: -$0.38Sep '25Dec 2025: $1.08Dec '25Mar 2026: -$0.05Mar '26Jun 2026: -$0.05Jun '26Sep 2026: -$0.07Sep '26Latest -$0.07
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $500,000Jun '26Sep 2026: $0Sep '26Latest $0
How PALI moved after its last 5 reports
Average move the session after a report ±3.1%
Nov 10, 2026After the close+3.5%
Aug 10, 2026After the close+1.9%
May 12, 2026After the close−2.6%
Mar 27, 2024After the close+1.0%
Mar 23, 2021After the close−6.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PALIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PALI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PALI

Technical Analysis

PALI · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 33% below its 20 day and 63% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot S1 at $0.80, and the nearest resistance the 52 week low at $0.84.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 11.2%/day
Key levels
$2.8552 week high+239.3%
$1.81200 day average+115.5%
$1.70100 day average+102.4%
$1.3750 day average+63.1%
$1.30Swing high (Nov 4)+54.8%
$1.1220 day average+33.3%
$0.92Pivot R1+9.5%
$0.88Pivot+4.8%
$0.8452 week low+0.0%
$0.84Last close
$0.80Pivot S1−4.8%
Indicators
RSI (14)24.56Oversold below 30Oversold
MACD-0.13Below its signal lineBearish
Stochastic1.0Near the bottom of its rangeOversold
ADX (14)43.6Strong downtrend
Williams %R-99.6Oversold below −80, overbought above −20Oversold
CCI (20)-208.8Oversold below −100, overbought above 100Oversold
Rate of change−25.7%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 11.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PALI

What happened before

See how PALI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PALI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PALI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PALIHow many large options trades hit PALI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PALI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●57 buying vs 53 selling
  • ▲Held by funds +2.7 pts
  • ▼Funds holding -8
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding116124−6.5%
In funds' top 10110.0%
Held by funds99.4%96.7%+2.7 pts
New / increased17 / 4049 / 33−30.5%
Reduced / sold out28 / 2523 / 21+20.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PALI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PALI Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$347K7 buys · 2 insiders
Sold$420K4 sales · 2 insiders
2026-01 bought $18K2026-02 sold $10K2026-07 bought $250K2026-07 sold $410K2026-10 bought $29K2026-11 bought $50KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Robert Baltera Jr.DirectorBuy50,000$1.01$50K
Oct 2Donald Allen WilliamsDirectorBuy20,000$1.44$29K
Jul 9Robert Baltera Jr.DirectorBuy45,000$1.97$89K
Jul 7Robert Baltera Jr.DirectorBuy50,000$2.04$102K
Jul 7John David FinleyCeo, CFOSale146,798$2.07$303K
Jul 7Mitchell Lawrence JonesChief Medical OfficerSale51,880$2.05$107K
Every insider buy and sale for PALI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PALI insider trades →

From SEC Form 4 filings by PALI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PALI is in one of them and how their past PALI trades turned out.

PALI in the AI portfolios
Loading…

PALI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PALI in an article yet. Here's the latest on the wider market.

PALI in the news

About Palisade Bio

Palisade Bio is a biopharmaceutical company based in Carlsbad, California, that is developing oral medicines for inflammatory bowel disease. Its lead candidate, PALI-2108, is a pill taken once a day that stays inactive until it reaches the lower intestine, where gut bacteria convert it into an active drug at sites of inflammation. The company is testing the candidate in people with ulcerative colitis and Crohn's disease. Its candidates are still in clinical testing and are not yet on the market.

Headquarters
Carlsbad, CA